Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity Hospital, Bordeaux
About this trial
The study aims at identifying the type of B and CD4 T cell subsets with pathogenic properties in the different clinical forms of multiple sclerosis. This research might open new therapeutic approaches for the treatment of multiple sclerosis particularly progressive MS.
Eligibility criteria
Qualifiers
male or female subjects ;
Age ≥ 18 years;
subjects with MS defined by 2010 revised McDonald criteria or presenting a clinical isolated syndrome;
patients for which a blood draw and / or lumbar puncture to collect CSF is performed for diagnostic or therapeutic purpose;
Disqualifiers
Pregnant or breastfeeding women,
patient concerned by articles L 1121-5 to L 1121-8 (persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent)
Trial design
Treatments tested in this trial
- blood sample
- cerebro-spinal fluid
Treatment groups
150 Participants
are divided into 1 treatment groupSponsors and collaborators
University Hospital, Bordeaux
Lead sponsor
University of Bordeaux
Collaborator
Source ClinicalTrials.gov